Breast HER2 Insitu Hybridization (HER2 ISH): Acceptable and unacceptable staining criteria impacting on interpretation

被引：0
|
作者：
Parry, S. [1 ]
Miller, K. [1 ]
Ibrahim, M. [1 ]
机构：
[1] UK NEQAS ICC & ISH, London, England
来源：
VIRCHOWS ARCHIV | 2012年 / 461卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：S258 / S258
页数：1
相关论文
共 50 条
  • [41] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04): : 535 - 540
  • [42] HER2 0, HER2 1+and HER2 2+/FISH Negative Primary Breast Cancers Are Biologically Distinct
    Donahue, Nolan
    Aragao, Alessa
    Gordezky, Rachel
    Haddad, Sandra
    Tang, Ping
    LABORATORY INVESTIGATION, 2024, 104 (03) : S146 - S148
  • [43] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [44] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [45] Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma Implications for Clinical HER2 Testing and Interpretation
    Buza, Natalia
    Hui, Pei
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2023, 147 (03) : 331 - 337
  • [46] In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
    Melanie Spears
    Karen J. Taylor
    Alison F. Munro
    Carrie A. Cunningham
    Elizabeth A. Mallon
    Chris J. Twelves
    David A. Cameron
    Jeremy Thomas
    John M. S. Bartlett
    Breast Cancer Research and Treatment, 2012, 132 : 463 - 470
  • [47] HER2 cytoplasmic staining and penile cancer
    Silva, Alice M.
    Cunha, Isabela W.
    Guimaraes, Gustavo C.
    Cubilla, Antonio
    Lopes, Ademar
    Soarea, Fernando A.
    CANCER RESEARCH, 2012, 72
  • [48] Nonmembranous HER2/neu immunohistochemical staining
    Vera-Román, JM
    Rubio, L
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2003, 11 (04): : 364 - 365
  • [49] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [50] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
12345